ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 115 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2020. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $733,300 | -22.5% | 30,115 | +7.5% | 0.01% | -28.6% |
| Q1 2024 | $945,999 | +6.3% | 28,013 | -0.7% | 0.01% | 0.0% |
| Q4 2023 | $889,777 | +14.8% | 28,220 | -6.9% | 0.01% | +16.7% |
| Q3 2023 | $774,753 | +38.4% | 30,323 | +55.3% | 0.01% | +20.0% |
| Q2 2023 | $559,948 | +160.4% | 19,524 | +34.8% | 0.01% | +150.0% |
| Q3 2022 | $215,000 | -13.0% | 14,481 | -7.6% | 0.00% | 0.0% |
| Q2 2022 | $247,000 | -66.2% | 15,677 | -42.2% | 0.00% | -75.0% |
| Q1 2022 | $731,000 | -35.3% | 27,102 | -11.2% | 0.01% | -38.5% |
| Q4 2021 | $1,129,000 | -26.7% | 30,505 | -5.4% | 0.01% | -13.3% |
| Q3 2021 | $1,541,000 | +31.4% | 32,259 | -6.9% | 0.02% | +50.0% |
| Q2 2021 | $1,173,000 | -12.1% | 34,665 | +11.5% | 0.01% | -50.0% |
| Q3 2020 | $1,334,000 | +2.1% | 31,101 | +11.3% | 0.02% | +11.1% |
| Q2 2020 | $1,307,000 | – | 27,953 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Portolan Capital Management | 484,907 | $11,807,485 | 0.97% |
| Nikko Asset Management Americas, Inc. | 1,563,065 | $37,966,849 | 0.44% |
| Diametric Capital, LP | 32,765 | $797,827 | 0.43% |
| ARK Investment Management | 1,964,964 | $47,846,871 | 0.42% |
| SummerHaven Investment Management, LLC | 23,400 | $569,790 | 0.38% |
| Quantedge Capital Pte Ltd | 40,800 | $993,480 | 0.36% |
| Granahan Investment Management | 344,549 | $8,389,768 | 0.34% |
| FEDERATED HERMES, INC. | 4,694,060 | $114,300,361 | 0.27% |
| Belmont Capital, LLC | 40,000 | $974,000 | 0.18% |
| Woodline Partners LP | 754,023 | $18,360,460 | 0.18% |